Feline leukemia virus vaccines |
| OF THE INVENTION Any immunogenic FeLV protein may be expressed in baculovirus following the ... |
|
Resolution of D,L-dehydroproline |
| I claim: 1. A method for the preparation of L-3,4-dehydroproline comprising in combination the ... |
|
Quaternary salts as hypoglycemic agents |
| OF THE INVENTION The hypoglycemic agents of the present invention are synthesized by the reaction ... |
|
Pasteurized therapeutically active protein compositions |
| What is claimed is: 1. A method of pasteurizing a composition comprising a thermally sensitive, ... |
|
Method of preparing a high-purity, virus safe, biologically active transferrin preparation |
| We claim: 1. A method of preparing a high-purity, virus-safe biologically active, transferrin ... |
|
Hydrolyzable resin composition and an antifouling coating composition containing the same |
| What is claimed is: 1. A method of preventing marine fouling which comprises applying to a surface ... |
|
Treatment for herpes virus |
| OF THE INVENTION According to the invention, I provide a composition for and method of use of such ... |
|
Microbicidal meta oxy- and thio-substituted phenylanilines |
| What is claimed is: 1. A compound of the formula I, including salts and metal complexes thereof ##ST... |
|
|
Novel saframycin A derivatives and process for producing the same
| Details |
Inventors: Arai, Tadashi; Mikami, Yuzuru;
Assignee: Arai; Tadashi (Tokyo, JP)
Primary Examiner: Wiseman; Thomas G.
Assistant Examiner: Patterson, Jr.; Charles L.
Attorney, Agent or Firm: Wenderoth, Lind & Ponack
Disclosed are compounds of the formula ##STR1## wherein R represents hydrogen or C.sub.1 -C.sub.4 -alkyl. These compounds are obtained by fermentation of the known saframycin A producing strain Streptomyces lavendulae No. 314 and by reaction with the amino acids L-tyrosine, L-methionine, glycine and HOOC-(CH)NH.sub.2 -CH.sub.2 -R. When R is hydrogen, saframycin Y.sub.3 and when R is methyl, saframycin Y.sub.d-1 are produced. |
|
DETAILED DESCRIPTION What is claimed is: 1. A process for the preparation of a compound of the formula ##STR4## wherein R represents hydrogen or C. sub. 1 -C. sub. 4 -alkyl comprising (a) suspending a biomass of a strain of streptomyces capable of producing saframycin A in an aqueous medium; (b) adding to said suspension glycine, L-tyrosine, L-methionine, and an amino acid of the formula HO. sub. 2 CCH(NH. sub. 2)--CH. sub. 2 --R (II) wherein R is as defined above, either as individual amino acids or peptides consisting of amino acids selected from glycine, L-tyrosine, L-methionine, and the amino acid of formula II, or mixtures of said amino acids and said peptides to yield an enriched suspension; (c) incubating said enriched suspension; (d) filtering the result of step c; and (e) adding a cyanide salt to the filtrate obtained from step d to result in said compound of formula I. 2. The process of claim 1 which further comprises isolating said compound of formula I from the result of step e. 3. The process of claim 1 which further comprises converting said compound of formula I to an acid addition salt thereof. 4. The process of claim 3 wherein said acid addition salt is pharmaceutically acceptable. 5. The process of claim 1 wherein said biomass is obtained by inoculating a culture medium containing a carbon source, a nitrogen source, and essential trace elements with a strain of streptomyces capable of producing saframycin A; culturing said inoculated medium at a temperature of about 25. degree. C. to about 35. degree. C. , at a pH of about 4. 0 to about 7. 5, under aerobic conditions to yield a biomass in said culture; and isolating said biomass therefrom. 6. A process for the preparation of a compound of the formula ##STR5## wherein R represents hydrogen comprising (a) suspending a biomass of a strain of streptomyces capable of producing saframycin A in an aqueous medium; (b) adding to said suspension glycine, L-tyrosine, and L-methionine, either as individual amino acids or as peptides consisting of glycine, L-tyrosine, and L-methionine, or mixtures of said amino acids and said peptides to yield an enriched suspension; (c) incubating said enriched suspension; (d) filtering the result of step c; (e) adding a cyanide salt to the filtrate obtained from step d to result in said compound of formula I; and (f) then isolating the compound of formula I
|
| Related patents |
|
|
Process for the preparation of a new-type active substance selectively inhibiting food intake
What we claim is: 1. A process for isolating a food intake suppressant from human or animal blood serum which comprises subjecting the human and/or animal blood serum to ...
|
|
|
Terminal methionyl bovine growth hormone and its use
According to the present invention, synthetic DNA is provided for a substantial portion of the initial coding sequence of a heterologous gene insert, and optionally, ...
|
|
|
Human immune interferon
The present invention is based upon the discovery that recombinant DNA technology can be used to successfully produce human immune interferon, preferably in direct form, ...
|
|
|
Method for production of an enzyme granulate
I claim: 1. In a process for production of an enzyme granulate which comprises granulating an enzyme composition comprising enzyme, filler, binder, and from 1.5-40% by ...
|
|
|
Process for preparing narasin
The new microorganism of this invention is a biologically pure culture derived from a soil sample collected near the Surinam River, Surinam, South America. The culture ...
|
|
|
Reversible optical waveguide vapor sensor
Accordingly, it is an object of the invention to detect small amounts of a chemical in air and in other gases. Another object is to provide a device for such purpose ...
|
|
|
Biotinidase-resistant biotinylated compound and methods of use thereof
This invention relates to biotinidase-resistant biotinylated compounds containing a chemical fragment having the structure: ##STR2## wherein R.sub.1 and R.sub.3 are ...
|
|
|
Method of recovering shiga-like toxins and vaccines comprising inactivated shiga-like toxin
This invention provides a facile, efficient and reproducible method for recovering biologically active Shiga-like toxins from a sample using an affinity ligand ...
|
|
|
Assays for shiga toxin and shiga-like toxins
OF THE INVENTION The present invention relates to a substantially pure antigenic or peptide protein related to Shiga toxin (ST) or Shiga-like toxins I or II (SLT-II, SLT...
|
|
|
Control of enterohemorrhagic E. coli 0157:H7 in cattle by probiotic bacteria and specific strains of E. coli
OF THE INVENTION Histologic examination of colonic tissue has revealed no evidence of attachment of E. coli O157:H7 to bovine colonic tissue. The rumen appears to be ...
|
|
|